Current Crizotinib News and Events | Page 3

Current Crizotinib News and Events, Crizotinib News Articles.
Sort By: Most Relevant | Most Viewed
Page 3 of 3 | 120 Results
Targeted therapy boosts lung cancer outcomes
Non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy. Median progression-free survival was 7.7 months in the crizotinib group and three months in the chemotherapy group. Patients treated with crizotinib also reported a better quality of life than those treated with standard chemotherapy. (2013-06-01)

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die -- the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even in the face of p53 reactivation create more of the protein p21 than the protein PUMA; tumors that die have more PUMA than p21. And, for the first time, the current study shows a handful of genes that control this ratio. (2013-05-22)

Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
A study published this week in the journal Cancer confirms the finding of low-testosterone in crizotinib patients, and for the first time details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can alleviate this side effect in many patients. (2013-04-16)

Alexander Levitzki of Hebrew University chosen for cancer research award
The American Association for Cancer Research has chosen professor Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research. (2013-04-08)

Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. It also displayed greater antitumor activity and prolonged survival in a mouse model. Ganetespib has potential as a new option for treating ALK-dependent lung cancers. (2013-03-26)

Study shows immunohistochemistry is reliable screening tool for ALK rearrangement
A recent study published in the January 2013 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, concludes immunohistochemistry is a reliable screening tool for identification of ALK rearrangement. (2012-12-15)

Novel test identifies patients most likely to benefit from ALK inhibition therapy
Researchers have now developed and tested a promising new method for screening anaplastic lymphoma kinase fusions in non-small cell lung carcinoma. This new diagnostic assay offers a cost-effective and easy-to-perform alternative to existing tests. (2012-12-12)

Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'
This study of 65 patients showed that continuing either crizotinib or erlotinib after the treatment of resistant pockets with focused radiation ( (2012-12-01)

Drug resistance biomarker could improve cancer treatment
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published by Cell Press November 21st in the journal Cell. The study reveals a biomarker that can predict responses to cancer drugs and offers a strategy to treat drug-resistant tumors based on their genetic signature. (2012-11-21)

Study shows different approach after progression in non-small cell lung cancer patients
A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered. (2012-11-15)

Molecular 'portraits' of tumors match patients with trials in everyday clinical practice
Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments and phase I clinical trials -- an approach that could become part of everyday clinical practice. The research is presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. (2012-11-08)

Of mice and men
A known drug, imatinib, can be used to treat a highly aggressive type of lymphoma. The animal model study also demonstrating a striking success in a human patient was largely undertaken in the group of Lukas Kenner at the Ludwig Boltzmann Institute for Cancer Research and the Medical University of Vienna with the support of Karoline Kollmann and Veronika Sexl at the Vetmeduni Vienna and others. The findings are published in (2012-10-15)

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. (2012-09-30)

New weapons in the fight against cancer
Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. (2012-09-30)

Crizotinib reduces tumor size in patients with ALK positive lung cancer
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. (2012-09-06)

Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
A recent University of Colorado Cancer Center case study published in the Journal of Thoracic Oncology describes the never-before-seen case of a patient who tested negative for EML4-ALK fusion based on the well-defined criteria for FISH assay as approved by FDA, but nevertheless experienced remission after treatment with crizotinib. (2012-08-28)

Chromosomal translocations point the way toward personalized cancer care
A recent University of Colorado Cancer Center review published in the journal Frontiers of Medicine shows the role of chromosomal translocations in causing a range of cancers. Emerging, personalized therapies target these translocations. (2012-08-13)

Scientists develop new strategy to overcome drug-resistant childhood cancer
A new drug combination could offer hope to children with neuroblastoma - one of the deadliest forms of childhood cancer - by boosting the effectiveness of a promising new gene-targeted treatment. Researchers at the Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called crizotinib, which recently showed positive early results in its first trial in children with cancer. (2012-07-11)

New therapy on the horizon for ALK+ non-small cell lung cancer
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib -- the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3. (2012-06-01)

ASCO releases studies from upcoming annual meeting
The American Society of Clinical Oncology today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO's 47th Annual Meeting. (2012-05-16)

Children with cancer have complete responses in a Children's Oncology Group phase 1 trial
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children's Oncology Group. (2012-05-16)

Clinical insight improves treatment with new lung cancer drug
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. (2012-04-04)

Combined inhibition of VEGF and c-MET can decrease metastasis
Dual inhibition of vascular endothelial growth factor and c-MET signaling inhibited tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer, according to a paper published in Cancer Discovery. (2012-02-24)

Using online patient communities and new trial approaches to optimize clinical research
Dr. Howard West, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, and Dr. Ross Camidge, director of the Thoracic Oncology Clinical Program at the University of Colorado School of Medicine are looking for ways to help patients tackle these geographic barriers using both online patient communities and innovative trial approaches. (2012-02-15)

New research confirms need for lung cancer testing
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer show distinct patterns of spread in the body. (2012-02-02)

Massachusetts General study defines a new genetic subtype of lung cancer
Investigators at the Massachusetts General Hospital Cancer Center have defined the role of a recently identified gene abnormality - rearrangements in the ROS1 gene - in a deadly form of lung cancer. ROS1-rearranged tumors represent one to two percent of non-small-cell lung cancers, the leading cause of cancer death in the US. The researchers also show that ROS1-driven tumors can be treated with crizotinib and describe the remarkable response of one patient to crizotinib treatment. (2012-01-31)

Advance in lung cancer treatment
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase positive advanced non-small cell lung cancer becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib. (2012-01-18)

In a childhood cancer, basic biology offers clues to better treatments
By studying tumor biology at the molecular level, researchers are gaining a deeper understanding of drug resistance -- and how to avoid it by designing pediatric cancer treatments tailored to specific mutations in a child's DNA. Their target is neuroblastoma, an often-deadly cancer of the peripheral nervous system. (2011-11-09)

TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma. (2011-09-21)

First and only therapeutic drug for ALK-positive lung cancer approved
FDA approves the drug crizotinib for use with a subset of lung cancer patients known as ALK-positive -- a (2011-08-31)

Study: Inexpensive method detects ALK rearrangement in lung cancer patients
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer. (2011-08-02)

ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
ALK rearrangement has been found in 9.6 percent of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1 percent, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer. (2011-07-05)

Benefit of targeted lung cancer therapy confirmed
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology. (2011-06-03)

Clinical observation leads to lung cancer discovery
A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease. (2011-03-07)

UCI non-small cell lung cancer study highlights advances in targeted drug therapy
A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine. (2010-11-01)

People with specific kind of lung cancer respond to new targeted treatment
A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer. (2010-10-28)

'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine. (2010-10-27)

New targeted lung cancer drug produces 'dramatic' symptom improvement
A clinical trial of a new targeted drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. The multi-institutional research team reports that daily doses of crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase gene and suppressed tumor growth in another one-third of study participants. (2010-10-27)

SWOG names 5 cancer researchers outstanding Young Investigators
SWOG, one of the nation's largest cancer clinical trial cooperative groups, has selected five talented researchers for its Young Investigators Training Course, an intensive, three-day workshop in how to develop and conduct cancer clinical trials. (2010-09-08)

New lung cancer drug shows dramatic results for shrinking tumors
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials. (2010-06-22)

Page 3 of 3 | 120 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.